Home  |  Contact

UniProtKB/Swiss-Prot P81172: Variant p.Gly71Asp

Hepcidin
Gene: HAMP
Chromosomal location: 19q13.1
Variant information

Variant position:  71
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Aspartate (D) at position 71 (G71D, p.Gly71Asp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and acidic (D)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Hemochromatosis 2B (HFE2B) [MIM:613313]: A juvenile form of hemochromatosis, a disorder of iron metabolism with excess deposition of iron in a variety of organs leading to their failure, bronze skin pigmentation, hepatic cirrhosis, arthropathy and diabetes. The most common symptoms of juvenile hemochromatosis at presentation are hypogonadism and cardiomyopathy. {ECO:0000269|PubMed:12915468, ECO:0000269|PubMed:14630809, ECO:0000269|PubMed:14633868, ECO:0000269|PubMed:14670915, ECO:0000269|PubMed:15099344}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In HFE2B.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  71
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  84
The length of the canonical sequence.

Location on the sequence:   PMFQRRRRRDTHFPICIFCC  G CCHRSKCGMCCKT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PMFQ-RR-RRRDTHFPICIFCCGCCHRSKCGMCCKT

                              PTLQLRRLRRRDTHFPICIFCCGCCKTPKCGLCC

Mouse                         IPMQ-KR-RKRDTNFPICIFCCKCCNNSQCGICC

Rat                           ALLMLKR-RKRDTNFPICLFCCKCCKNSSCGLCC

Pig                           PVAQ--R-LRRDTHFPICIFCCGCCRKAICGMCC

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Peptide 60 – 84 Hepcidin-25
Peptide 65 – 84 Hepcidin-20
Disulfide bond 66 – 82
Disulfide bond 69 – 72
Disulfide bond 70 – 78
Beta strand 66 – 71


Literature citations

Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload.
Biasiotto G.; Belloli S.; Ruggeri G.; Zanella I.; Gerardi G.; Corrado M.; Gobbi E.; Albertini A.; Arosio P.;
Clin. Chem. 49:1981-1988(2003)
Cited for: VARIANT HFE2B ASP-71;

Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis.
Merryweather-Clarke A.T.; Cadet E.; Bomford A.; Capron D.; Viprakasit V.; Miller A.; McHugh P.J.; Chapman R.W.; Pointon J.J.; Wimhurst V.L.; Livesey K.J.; Tanphaichitr V.; Rochette J.; Robson K.J.;
Hum. Mol. Genet. 12:2241-2247(2003)
Cited for: VARIANT HFE2B ASP-71;

HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype.
Jacolot S.; Le Gac G.; Scotet V.; Quere I.; Mura C.; Ferec C.;
Blood 103:2835-2840(2004)
Cited for: VARIANTS HFE2B GLY-59 AND ASP-71;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.